MedTrace Logo

Fibroscan Study in HCC

NCT01796145 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 207

Last updated 2025-11-17

No results posted yet for this study

Summary

In patients with HCC undergoing therapy 1. We aim to determine the prognostic significance of liver stiffness in patients with HCC 2. We aim to determine the rate and severity of complications of treatment and its association with liver stiffness in patients with HCC

Conditions

  • Confirmed Diagnosis of Hepatocellular Carcinoma
  • Patients Who Are Scheduled to Undergo Transarterial Chemobolization, Systemic Therapy Surgery
  • Child's A to C Cirrhosis

Interventions

OTHER

Fibroscan

Sponsors & Collaborators

  • Chinese University of Hong Kong

    lead OTHER

Principal Investigators

  • Stephen Lam Chan, FHKCP · Chinese University of Hong Kong

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-27
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01796145 on ClinicalTrials.gov